UK - Gov: COVID-19 variant Delta trend & Omicron becoming dominant, and now Omicron 2.....

[sharon sanders]

https://coronavirus.data.gov.uk/

[sharon sanders]

bump this

[sharon sanders]

https://coronavirus.data.gov.uk/

[sharon sanders]

bump this

[Mary Wilson]

COVID-19 vaccine surveillance report

Week 12
24 March 2022

UK Health Security Agency

Executive summary
Four coronavirus (COVID-19) vaccines have now been approved for use in the UK. Rigorous clinical trials have been undertaken to understand the immune response, safety profile and efficacy of these vaccines as part of the regulatory process. Ongoing monitoring of the vaccines as they are rolled out in the population is important to continually ensure that clinical and public health guidance on the vaccination programme is built upon the best available evidence.

UK Health Security Agency (UKHSA), formerly Public Health England (PHE), works closely with the Medicines and Healthcare Regulatory Agency (MHRA), NHS England, and other government, devolved administration and academic partners to monitor the COVID-19 vaccination programme. Details of the vaccine surveillance strategy are set on the pageCOVID-19: vaccine surveillance strategy (1). As with all vaccines, the safety of COVID-19vaccines is continuously being monitored by the MHRA. They conclude that overall, the benefits of COVID-19 vaccines outweigh any potential risks (2).

Vaccine effectiveness
Several studies of vaccine effectiveness have been conducted in the UK against different COVID-19 variants. Vaccine effectiveness against symptomatic disease with the Omicron variant is substantially lower than against the Delta variant, with rapid waning. However, protection against hospitalisation remains high, particularly after 3 doses.

Population impact
The impact of the vaccination programme on the population is assessed by taking into account vaccine coverage, evidence on vaccine effectiveness and the latest COVID-19 disease surveillance indicators.

Vaccine coverage tells us about the proportion of the population that have received one, 2 and 3 doses of COVID-19 vaccines. By 20 March 2022, the overall vaccine uptake in England for dose 1 was 69.5% and for dose 2 was 65.2%. Overall vaccine uptake in England in people with at least 3 doses was 50.8%. In line with the programme rollout, coverage is highest in the oldest age groups.

We present data on COVID-19 cases, hospitalisations and deaths by vaccination status. This raw data should not be used to estimate vaccine effectiveness as the data does not take into account inherent biases present such as differences in risk, behaviour and testing in the vaccinated and unvaccinated populations. Vaccine effectiveness is measured in other ways as detailed in the Vaccine effectiveness section below. ...

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1063023/Vaccine-surveillance-report-week-12.pdf

[sharon sanders]

https://coronavirus.data.gov.uk/

[sharon sanders]

bump this

[sharon sanders]

https://coronavirus.data.gov.uk/

[sharon sanders]

https://coronavirus.data.gov.uk/

[sharon sanders]

https://coronavirus.data.gov.uk/

[sharon sanders]

Omicron BA2.....

https://coronavirus.data.gov.uk/

[sharon sanders]

[sharon sanders]

bump this

[sharon sanders]

UK Health Security Agency

@UKHSA
·
8m
The #COVID19 Dashboard has been updated: http://coronavirus.data.gov.uk On 29 December 183,037 new cases and 57 deaths in 28 days of a positive test were reported in England and Wales. Our data includes the number of people receiving a first, second and booster dose of the #vaccine

20
41
41
UK Health Security Agency

@UKHSA
·
17m

[sharon sanders]

bump this